Quarterly report [Sections 13 or 15(d)]

Statements of Cash Flows (Unaudited) - Non-Cash Activities (Parenthetical)

v3.25.2
Statements of Cash Flows (Unaudited) - Non-Cash Activities (Parenthetical) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Supplemental disclosure of noncash activities related to the uBriGene Repurchase Transaction (see Note 4):    
Fair value of assets received $ 0 $ 2,209
Fair value of supplies received expensed to research and development 0 2,509
Accounts receivable written off 0 (6,967)
Accounts payable written off 0 3,644
Deferred purchase consideration $ 0 $ (1,395)